Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.07 EUR
57.87 M EUR
878.38 M EUR
676.83 M
About GENOMMA LAB INTERNACIONAL SAB
Sector
CEO
Marco Sparvieri
Headquarters
Mexico City
Website
Founded
1996
ISIN
MX01LA010006
FIGI
BBG000HLBKZ9
Genomma Lab Internacional SAB de CV engages in the development, manufacturing and marketing of pharmaceutical, beauty and personal care products. The company was founded by Rodrigo Alonso Herrera Aspra on October 30, 1996 and is headquartered in Mexico City, Mexico.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange GENOMMA LAB INT. FIN. B stocks are traded under the ticker GEKA.
We've gathered analysts' opinions on GENOMMA LAB INT. FIN. B future price: according to them, GEKA price has a max estimate of 1.55 EUR and a min estimate of 0.85 EUR. Watch GEKA chart and read a more detailed GENOMMA LAB INT. FIN. B stock forecast: see what analysts think of GENOMMA LAB INT. FIN. B and suggest that you do with its stocks.
GEKA reached its all-time high on Dec 6, 2013 with the price of 2.17 EUR, and its all-time low was 0.15 EUR and was reached on Mar 20, 2009. View more price dynamics on GEKA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track GENOMMA LAB INT. FIN. B financials in yearly and quarterly reports right on TradingView.
GENOMMA LAB INT. FIN. B is going to release the next earnings report on Feb 19, 2025. Keep track of upcoming events with our Earnings Calendar.
GEKA earnings for the last quarter are 0.03 EUR per share, whereas the estimation was 0.02 EUR resulting in a 22.22% surprise. The estimated earnings for the next quarter are 0.02 EUR per share. See more details about GENOMMA LAB INT. FIN. B earnings.
GENOMMA LAB INT. FIN. B revenue for the last quarter amounts to 232.13 M EUR, despite the estimated figure of 212.37 M EUR. In the next quarter, revenue is expected to reach 182.93 M EUR.
GEKA net income for the last quarter is 30.09 M EUR, while the quarter before that showed 32.15 M EUR of net income which accounts for −6.42% change. Track more GENOMMA LAB INT. FIN. B financial stats to get the full picture.
GENOMMA LAB INT. FIN. B dividend yield was 5.57% in 2023, and payout ratio reached 69.55%. The year before the numbers were 3.41% and 41.31% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jan 15, 2025, the company has 1.59 K employees. See our rating of the largest employees — is GENOMMA LAB INT. FIN. B on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GENOMMA LAB INT. FIN. B EBITDA is 182.54 M EUR, and current EBITDA margin is 21.13%. See more stats in GENOMMA LAB INT. FIN. B financial statements.
Like other stocks, GEKA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENOMMA LAB INT. FIN. B stock right from TradingView charts — choose your broker and connect to your account.